Sanofi SA (SNY)
48.67
-0.15
(-0.31%)
USD |
NASDAQ |
May 17, 16:00
48.65
-0.02
(-0.04%)
After-Hours: 20:00
Sanofi SG&A Expense (Quarterly): 2.830B for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 2.830B |
December 31, 2023 | 3.156B |
September 30, 2023 | 2.808B |
June 30, 2023 | 2.808B |
March 31, 2023 | 2.800B |
December 31, 2022 | 2.960B |
September 30, 2022 | 2.663B |
June 30, 2022 | 2.742B |
March 31, 2022 | 2.670B |
December 31, 2021 | 3.154B |
September 30, 2021 | 2.672B |
June 30, 2021 | 2.817B |
March 31, 2021 | 2.644B |
June 30, 2020 | 2.494B |
March 31, 2020 | 2.584B |
December 31, 2019 | 3.032B |
September 30, 2019 | 2.570B |
June 30, 2019 | 2.762B |
March 31, 2019 | 2.699B |
December 31, 2018 | 3.115B |
September 30, 2018 | 2.686B |
June 30, 2018 | 2.993B |
March 31, 2018 | 2.840B |
December 31, 2017 | 3.194B |
September 30, 2017 | 2.720B |
Date | Value |
---|---|
June 30, 2017 | 2.825B |
March 31, 2017 | 2.640B |
December 31, 2016 | 2.800B |
September 30, 2016 | 2.538B |
June 30, 2016 | 2.708B |
March 31, 2016 | 2.440B |
December 31, 2015 | 2.008B |
September 30, 2015 | 2.735B |
June 30, 2015 | 2.657B |
March 31, 2015 | 2.539B |
December 31, 2014 | 2.227B |
September 30, 2014 | 3.060B |
June 30, 2014 | 3.093B |
March 31, 2014 | 2.847B |
December 31, 2013 | 2.031B |
September 30, 2013 | 2.667B |
June 30, 2013 | 3.012B |
March 31, 2013 | 2.825B |
December 31, 2012 | 3.054B |
September 30, 2012 | 2.720B |
June 30, 2012 | 2.934B |
March 31, 2012 | 2.774B |
December 31, 2011 | 2.955B |
September 30, 2011 | 2.988B |
June 30, 2011 | 3.268B |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.494B
Minimum
Jun 2020
3.156B
Maximum
Dec 2023
2.787B
Average
2.781B
Median
SG&A Expense (Quarterly) Benchmarks
AstraZeneca PLC | 4.63B |
Novavax Inc | 86.80M |
Regeneron Pharmaceuticals Inc | 689.00M |
Fulcrum Therapeutics Inc | 10.06M |
Moderna Inc | 274.00M |